The effect of antiplatelet drugs on the management of cardiovascular diseases

Rohan R. Boralkar; Shweta S. Nilamwar; Pranjali P. Mane; Ashok B. Giri

doi:10.18203/2320-6012.ijrms20250712

Authors

Rohan R. Boralkar Department Pharmacy Practice, Shivalingeshwar College of Pharmacy, Almala, Maharashtra, India
Shweta S. Nilamwar Department Pharmacy Practice, Shivalingeshwar College of Pharmacy, Almala, Maharashtra, India
Pranjali P. Mane Department Pharmacy Practice, Shivalingeshwar College of Pharmacy, Almala, Maharashtra, India
Ashok B. Giri Department Pharmacy Practice, Shivalingeshwar College of Pharmacy, Almala, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20250712

Keywords:

Atherosclerosis, Ticagrelor, Aspirin, Clopidogrel, MI, Thrombosis

Abstract

Cardiovascular diseases (CVDs) are the leading global cause of mortality, necessitating innovative strategies for prevention, diagnosis, and treatment. Antiplatelet drugs play a vital role in mitigating adverse atherothrombotic events by inhibiting platelet aggregation, crucial for managing conditions such as myocardial infarction, ischemic stroke, and peripheral artery disease. Platelets, essential for haemostasis, also contribute to thrombus formation in vascular injury and disease. Their activation is triggered by stimuli like collagen, thrombin, and adenosine diphosphate (ADP). Antiplatelet drugs target these pathways to prevent arterial thrombosis. Key classes of antiplatelet agents include cyclooxygenase inhibitors, P2Y12 receptor antagonists, glycoprotein IIb/IIIa inhibitors, and phosphodiesterase inhibitors. Aspirin, a COX-1 inhibitor, irreversibly blocks thromboxane A2 production, effectively reducing recurrent cardiovascular events, though its role in primary prevention is tempered by bleeding risks. P2Y12 inhibitors, such as clopidogrel, prasugrel, and ticagrelor, suppress ADP-mediated platelet activation, with newer agents providing consistent efficacy but higher bleeding risk. Dual antiplatelet therapy, combining aspirin and a P2Y12 inhibitor, is the standard for acute coronary syndrome and post-PCI management. Challenges, including bleeding and resistance, underscore the need for personalized approaches using pharmacogenomics. Ongoing research aims to develop safer, targeted therapies, including thrombin receptor blockers and novel combination regimens.

Metrics

Metrics Loading ...

References

European Stroke Prevention Study 2 - American College of Cardiology. Available at: https://www.acc.org. Accessed on 21 September 2024,

Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. New England J Med. 2001;345(7):494–502. DOI: https://doi.org/10.1056/NEJMoa010746

Kunadian V, James SK, Wojdyla DM, Zorkun C, Wu J, Storey RF, Steg PG, Katus H, Emanuelsson H, Horrow J, Maya J. Angiographic outcomes in the PLATO trial (Platelet Inhibition and Patient Outcomes). JACC: Cardiovascular Interventions. 2013;6(7):671-83. DOI: https://doi.org/10.1016/j.jcin.2013.03.014

Jourdi G, Lordkipanidze M, Philippe A, Bachelot-Loza C, Gaussem P. Current and novel antiplatelet therapies for the treatment of cardiovascular diseases. International J Mol Sci. 2021;22(23):13079.

Virk HU, Escobar J, Rodriguez M, Bates ER, Khalid U, Jneid H, et al. Dual antiplatelet therapy: A concise review for clinicians. Life. 2023;13(7):1580. DOI: https://doi.org/10.3390/life13071580

Jourdi G, Lordkipanidzé M, Philippe A, Bachelot-Loza C, Gaussem P. Current and novel antiplatelet therapies for the treatment of cardiovascular diseases. Int J Mol Sci. 2021;22(23):3390. DOI: https://doi.org/10.3390/ijms222313079

PLATO. Wiki Journal Club. Available at: https://www.wikijournal. Accessed on 21 August 2024.

Wallentin L, Becker RC, Budaj A. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New England J Med. 2009;361(11):1045–57. DOI: https://doi.org/10.1056/NEJMoa0904327

Cattaneo M. Aspirin and clopidogrel: Efficacy, safety, and the issue of drug resistance. Arteriosclerosis, Thromb, and Vas Biol. 2004;24(11):1980–7. DOI: https://doi.org/10.1161/01.ATV.0000145980.39477.a9

Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circulation Research. 2007;100(9):1261–75. DOI: https://doi.org/10.1161/01.RES.0000264509.36234.51

Kunadian V, Sinclair H, Sutton A, Dangas GD. Aspirin, platelet p2y12 receptor inhibitors, and other oral antiplatelets: Comparative pharmacology and role in elective PCI. Int Cardiol Clin. 2013;2(4):527–35. DOI: https://doi.org/10.1016/j.iccl.2013.05.010

Cangemi R, Pignatelli P, Carnevale R. Platelet isoprostane overproduction in diabetic patients treated with aspirin. Diabetes. 2012;61(6):1626–32. DOI: https://doi.org/10.2337/db11-1243

Boden G, Homko C, Mozzoli M, Showe LC., Nichols, C. Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients. Diabetes. 2005;54(3):880–5. DOI: https://doi.org/10.2337/diabetes.54.3.880

Angiolillo DJ, Ueno M. Optimizing Platelet Inhibition in Clopidogrel Poor Metabolizers. JACC: Cardiovascular Interventions. 2011;4(4):411–4. DOI: https://doi.org/10.1016/j.jcin.2011.03.001

American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes. Diabetes Care. 2020;43(1):98–110. DOI: https://doi.org/10.2337/dc20-S009

Angiolillo DJ, Jakubowski JA. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. J Am Coll of Cardiol. 2014;64(10):1005–14. DOI: https://doi.org/10.1016/j.jacc.2014.06.1170

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J of the American College of Cardiol. 2019;49(14):1505–16. DOI: https://doi.org/10.1016/j.jacc.2006.11.044

Angiolillo DJ, Bernardo E, Ramírez, C, Costa MA. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J American Coll Cardiol. 2006;48(2):298–304. DOI: https://doi.org/10.1016/j.jacc.2006.03.038

Almutairi M, Al Batran R, Ussher JR. Glucagon-like peptide-1 receptor action in the vasculature. Peptides, 2019;111:26–32. DOI: https://doi.org/10.1016/j.peptides.2018.09.002

Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985;72(6):1177–84. DOI: https://doi.org/10.1161/01.CIR.72.6.1177

Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products; technical amendments. department of health and human services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Final rule; technical amendments. Fed Regist. 1999;64(177):49652-5.